According to Zacks, “Trinity Biotech plc, headquartered in Bray, the Republic of Ireland, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market worldwide. The company provides two haemostasis product lines, Biopool and Amax, comprising test kits and instrumentation used for the detection of blood disorders. These products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes and disorders of the blood, liver and intestine. The Company is also a provider of raw materials to the life sciences industry. It also engages in the provision of engineering, financial, and management services, as well as in trading business. Trinity Biotech sells its products through its sales force, as well as through a network of distributors and strategic partners. “
Separately, Stephens lowered shares of Trinity Biotech PLC from an overweight rating to an equal weight rating in a report on Wednesday, October 5th.
Shares of Trinity Biotech PLC (NASDAQ:TRIB) traded up 0.59% during trading on Friday, reaching $6.81. 112,011 shares of the company traded hands. The company has a market capitalization of $155.25 million, a P/E ratio of 51.20 and a beta of 1.19. The company’s 50-day moving average price is $7.96 and its 200-day moving average price is $10.86. Trinity Biotech PLC has a 52 week low of $5.76 and a 52 week high of $13.68.
Trinity Biotech PLC (NASDAQ:TRIB) last released its earnings results on Tuesday, October 25th. The company reported $0.07 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.07. The company earned $26.10 million during the quarter, compared to analyst estimates of $26.50 million. Trinity Biotech PLC had a net margin of 3.04% and a return on equity of 2.73%. Equities research analysts forecast that Trinity Biotech PLC will post ($1.67) EPS for the current fiscal year.
A number of large investors have recently made changes to their positions in TRIB. Paradice Investment Management LLC raised its stake in shares of Trinity Biotech PLC by 13.3% in the second quarter. Paradice Investment Management LLC now owns 1,626,496 shares of the company’s stock worth $18,444,000 after buying an additional 190,772 shares during the period. Janus Capital Management LLC raised its stake in shares of Trinity Biotech PLC by 1.3% in the second quarter. Janus Capital Management LLC now owns 1,432,059 shares of the company’s stock worth $16,240,000 after buying an additional 17,940 shares during the period. Heartland Advisors Inc. raised its stake in shares of Trinity Biotech PLC by 1.3% in the third quarter. Heartland Advisors Inc. now owns 1,269,435 shares of the company’s stock worth $16,782,000 after buying an additional 15,835 shares during the period. Bank of Montreal Can bought a new stake in shares of Trinity Biotech PLC during the second quarter worth about $8,242,000. Finally, Emerald Acquisition Ltd. bought a new stake in shares of Trinity Biotech PLC during the second quarter worth about $5,109,000. 70.55% of the stock is owned by institutional investors and hedge funds.
About Trinity Biotech PLC
Trinity Biotech plc (Trinity Biotech) develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The Company’s products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes, and disorders of the liver and intestine.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Trinity Biotech PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech PLC and related companies with MarketBeat.com's FREE daily email newsletter.